Pembrolizumab-Induced Eruptive Keratoacanthomas Managed With Intralesional Corticosteroids: A Case Report

Kevin Varghese1, Develyn Vetos1, Jason Woods1

  • 1Dermatology, University of Kansas Medical Center, Kansas City, USA.

Cureus
|June 4, 2026
PubMed
Summary

Pembrolizumab immunotherapy can cause eruptive squamous lesions. Intralesional triamcinolone effectively managed these immune-related skin events, allowing continued cancer treatment.